Table 3. . Targeted therapy for recurrent high-grade meningioma.

Inhibitor	Target	Patients (n)	Radiographic response rate (%)	Progression-free survival		Ref.
				Median (months)	6 month (%)
Bevacizumab	VEGF	15	0	6.5	44	[17]
Bevacizumab	VEGF	14	7	NA	86	[18]
Sunitinib	VEGFR	30	0	4.6	36	[19]
Vatalanib	VEGFR	21	5.8	4.65	37.5	[20]
Imatinib	PDGFR	10	0	2.0	0	[21,22]
Imatinib	PDGFR	8	0	16	66.7	[23]
Imatinib + hydroxyurea	PDGFR	13	0	4.1	46	[24]
Erlotinib	EGFR	17	0	3.6	29	[25]
Pasireotide	sst	17	0	4.0	12	[26]
Sandostatin® LAR	sst	8	25	3.0	25	[12]
Octreotide	sst	8	0	4.0	25	[27]
IFN-α	VEGF	35	0	3.0	17	–

NA: Not available; sst : Somatostatin receptor.

Data taken from [15].